Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,186
  • Shares Outstanding, K 418,564
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,619 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.70
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $0.00 on 05/29/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 unch
on 11/07/25
0.0200 -50.00%
on 10/20/25
-0.0050 (-33.33%)
since 10/07/25
3-Month
0.0100 unch
on 11/07/25
0.0200 -50.00%
on 10/20/25
-0.0100 (-50.00%)
since 08/07/25
52-Week
0.0050 +100.00%
on 03/25/25
0.0350 -71.43%
on 06/10/25
+0.0050 (+100.00%)
since 11/07/24

Most Recent Stories

More News
Revive Therapeutics Announces Closing of Second Tranche of Private Placement

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Announces Extension of Proposed Private Placement

TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“ Revive ” or the “ Company ”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to...

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Advances with Next-Generation Bucillamine Development

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics Announces Proposed Shares for Debt Transaction

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

RVV.CN : 0.0100 (-33.33%)
RVVTF : 0.0086 (-6.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as...

See More

Key Turning Points

3rd Resistance Point 0.0100
2nd Resistance Point 0.0100
1st Resistance Point 0.0100
Last Price 0.0100
1st Support Level 0.0100
2nd Support Level 0.0100
3rd Support Level 0.0100

See More

52-Week High 0.0350
Fibonacci 61.8% 0.0235
Fibonacci 50% 0.0200
Fibonacci 38.2% 0.0165
Last Price 0.0100
52-Week Low 0.0050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar